Drug Search Results
More Filters [+]

Forigerimod

Alternative Names: forigerimod, lupuzor, ipp-201101, ipp201101, ipp 201101
Latest Update: 2023-03-31
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: ImmuPharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Forigerimod

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Lupus Erythematosus, Systemic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

IP-006

P3

Completed

Lupus Erythematosus, Systemic

2019-02-05

72%

2017-004060-35

P3

Completed

Lupus Erythematosus, Systemic

2019-02-05

A study to evaluate the effectiveness and safety of the study drug for patients with SLE.

P3

Completed

Lupus Erythematosus, Systemic

2018-01-24

LUPUZOR

P3

Completed

Lupus Erythematosus, Systemic

2018-01-01

Recent News Events